Human papillomaviruses (HPVs) are small DNA tumor viruses, some of which induce malignancy in genital, anal, head and neck and also skin tissues. Vulval intraepithelial neoplasia (VIN) and cervical cancer are commonly associated with human papillomavirus (HPV) type 16 infection. This discovery has provided the opportunity for an immunotherapeutic approach to the treatment of these conditions. HPV infection by one or more âhigh-riskâ or âoncogenicâ types, most commonly 16 and 18, are present in 90-100% of invasive and grade 3 intraepithelial cervical lesions and in the majority of noncervical anogenital neoplasias. HPV oncogenes E6 and E7 play a crucial role in lower genital tract carcinogenesis and are required for maintenance of the transformed state and malignant phenotype. This makes the HPV16 E6 and E7 oncoproteins attractive targets for immunotherapy because they are exclusively expressed in virally infected and neoplastic cells, never in normal or healthy cells.
Evaluation of Pre-Clinical Efficacy to HPV16 L2E6E7 Vaccine and HPV16 E6E7 Adenovirus-5 Vector Vaccine with Different Dosages and Prime- Booster Regiments in Mouse Model: Zhuang Fang-Cheng, Chen Gang, Wu Jie, Jin Su-feng, Jiang Yun-shui, Gao Men, Li Jian-buo, Zhao Li, Mao Zian and Tian Houwen
Last date updated on September, 2020